Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Офтальмология / Учебные материалы / Color Atlas of Ophthalmology The Quick-Reference Manual for Diagnosis and Treatment

.pdf
Скачиваний:
0
Добавлен:
28.03.2026
Размер:
10.7 Mб
Скачать

13 Neuro-Ophthamology 401

Differential Diagnosis

Myasth en ia gravis, orbit al disease, oth er supran uclear m ovem en t disordersManagement

Work up an d m an age according to th e cause.

D

Fig . 13.17 (Continued) (D) Type III

 

INO. (E) Eye m ovements.

E

402 Color Atlas of Ophthalm ology

One -and-a-Half Syndrome

On e-an d -a-h alf syn drom e is also kn ow n as paralyt ic pont ine exotropia.

Presentation

In th e prim ar y posit ion th e eye th at is opposite th e side of th e lesion is exot ropic. Th e eye on th e sam e side of th e lesion looks st raigh t ah ead . Th e lesion is in th e pon t in e param edian ret icu lar form at ion (pon t in e gaze cen ter) or sixth -n er ve n u - cleus an d ipsilateral m edial longit u din al fascicu lus (Fig. 13.18A). From th e figu re on e w ill un derstan d th at on ly th e sixth n er ve on th e side opposite th e side of th e lesion w ill w ork. Th e pat ien t is n ot able to gaze w ith eith er eye tow ard th e side of th e lesion an d is n ot able to adduct th e eye on th e side of th e lesion (Fig. 13.18B). Th is is w hy th is is called on e-an d -a-h alf syn drom e, because on on e side gaze is absen t an d on th e oth er side on ly h alf th e gaze m ovem en t is presen t .

Differential Diagnosis

Myasth en ia gravis, orbit al disease, oth er supran uclear m ovem en t disorders

A

 

Fig . 13.18 (A) One -and-a-half syndrome.

 

(B) One -and-a-half syndrome. MLF, medial

 

longitudinal fasciculus; PGC, pontine gaze

B

center.

13 Neuro-Ophthamology 403

Management

Work up an d m an age according to th e cause.

Progressive Supranuclear Palsy

In progressive supran uclear palsy th ere is loss of n er ve cells, vascu lar degen era- t ion , an d glial react ion s in th e basal ganglia an d m idbrain .

Presentation

Th e first m an ifest at ion of progressive su pran u clear palsy is an in abilit y to m ake ver t ical saccades, par t icularly dow nw ard saccades. At th is poin t , th e p at ien ts bang th eir sh in s, eat off on ly th e top par t of th eir plates, an d com p lain of being u n able to read (th ey can n ot look dow n ). As th e disease progresses, h orizon tal fast m ove- m en ts becom e involved as w ell. Even t u ally, occular m ovem en t s cease to be sm ooth an d rapid . Pu rsuit m ovem en t s becom e ch aracterist ically cogw h eel.

Differential Diagnosis

Ch ron ic progressive extern al oph th alm oplegia, m yasth en ia gravis, brain stem lesion s, cavern ou s sin u s syn drom e

Management

No t reat m en t is available except su ppor t ive care.

Parinaud Syndrome

Th ere are several m an ifest at ion s of lesion s in th e collicular area. Th e sign s are th ough t to be cau sed by pressure an d distor t ion of u n derlying st ru ct u res in th e m idbrain an d n ot by dam age to specific path w ays t raversing th e colliculi. Th e gen - eral n am e for th e clin ical pict u re produced is kn ow n as Parinaud syndrom e.

Presentation

Any com bin at ion of im paired u pw ard gaze, im paired dow nw ard gaze, pu pillar y abn orm alit ies, or loss of accom m odat ion reflex can occu r. In gen eral, loss of u p - w ard gaze associated w ith dilated pu pils th at are fixed to ligh t suggests a lesion at th e level of th e su perior collicu lu s. Loss of dow nw ard gaze, n orm al p upillar y react ion s to ligh t , an d loss of convergen ce suggest th at th e lesion is sligh tly low er in th e area of th e in ferior colliculu s. It cou ld be du e to lesion s of th e pin eal glan d, m u lt iple sclerosis, vascu lar diseases, or Wern icke en ceph alopathy.

A special t ype of nystagm u s, ret ractor y nyst agm us, is presen t . Th is is a ver y rare sign of disease in th e collicular area an d con sist s of an inw ard an d ou t w ard m ove- m en t of both eyes w h en th e pat ien t at tem pts to look upw ard . Presu m ably, it is produ ced by all th e ext raocular m u scles act ing sim ult an eou sly—jerking th e globe back in to th e orbit or at tem pted u pw ard gaze—in an at tem pt to overcom e th e in - abilit y to look u pw ard .

Differential Diagnosis

Thyroid orbitopathy, cavern ous sin us syn drom e, m yasth en ia gravis

Management

Work up an d m an age according to th e cause.

404 Color Atlas of Ophthalm ology

Chronic Progressive External Ophthalmoplegia

Presentation

Th e clin ical feat u res are th e involvem en t of th e u pgaze an d th en th e lateral m ove- m en ts an d m ay later be affected in all gaze result ing in a fixed globe. Becau se th e m u scle involvem en t is sym m et rical, diplopia does n ot usu ally occu r. Th ere is also slow ly p rogressive bilateral ptosis.

Kearn s-Sayre syn drom e is a m itoch on drial cytopathy in h erited from th e m oth er. It is ch aracterized by pigm en t ar y ret in opathy w ith coarse gran ularit y. Con duct ion defects of th e h ear t can occu r. Hear t block m ay result in sudden death . Oth er fea- t u res are sh or t st at u re, m uscle w eakn ess, cerebellar ataxia, n eu rosen sor y deafn ess, m en tal h an dicap, an d delayed pu ber t y.

Differential Diagnosis

Oth er causes of paralyt ic an d rest rict ive st rabism us, m yop ath ies, m yasth en ia gravis, supran uclear palsies

Management

Treat th e associated con dit ion s. Use lu brican ts for th e exposure keratopathy an d base-dow n prism s w ith in reading glasses if th e dow ngaze is rest ricted . Pacem aker m ay be requ ired for th e cardiac con dit ion . In oculop h ar yngeal dyst rophy, dysph agia, an d recu rren t asp irat ion s m ay w arran t cricoph ar yngeal su rger y. Gen et ic cou n seling is n eeded .

14 Ophthalmic Pharmacology

Jam es M. Hill, Jean T. Jacob, Lori Vidal Denham , Blake A. Booth, Duncan A. Friedm an, Jeffery A. Hobden, Andrea T. Murina, Marie D. Acierno, Herbert E. Kaufm an, and Donald R. Bergsm a

Tw o gen eralizat ion s can be m ade abou t ph arm acological agen ts. First , all drugs h ave m ore th an on e effect . Secon d, all drugs can be toxic. Cert ain ly, m ost drugs h ave a p rim ar y m ech an ism of act ion , an d m any drugs are safe an d w ell tolerated . How ever, ever yon e sh ould be aw are of th e possible u n in ten ded con sequ en ces of any p h arm acological agen t . Alth ough m ost oph th alm ic drugs are adm in istered th rough topical applicat ion , even w ith th is t ype of drug deliver y, both topical an d system ic toxicit y can occur. Th is review h igh ligh ts th e m ost frequen t an d m ost severe toxicit ies bu t does n ot give an exh aust ive list ing of all side effect s of th ese oph th alm ic drugs. Th e gen eric n am e an d th e p rim ar y t rade n am e of th e dr ugs are given . W h en approp riate, w e h ave based th e review on th e class of th e drug an d h ave selected agen ts th at are m ost u sed to be in cluded in th is review . Fin ally, th is review is n ot m ean t to be an exh au st ive review of all oph th alm ic drugs but outlin es th e m ost im por tan t an d m ost frequ en tly u sed agen t s.

Antibacterial Agents

Topical Antibacterial Agents

Treat m en t of ocu lar in fect ious diseases (Fig. 14.1) involves eith er topical adm in - ist rat ion of an t im icrobial agen t s (for corn eal, conju n ct ival, an d lid m argin in fection s) or direct inject ion of th erapeu t ic agen ts in to th e eye it self (for posterior eye in fect ion s).

Table 14.1 list s com m ercially available an t ibacterial agen t s u sed topically as prophylaxis for surgical procedu res or for t reat ing corn eal u lcers, conju n ct ivit is, or m argin al lid disease. Most of th ese an t ibiot ics are broad spect r um , covering both gram -p osit ive an d gram -n egat ive path ogen s, yet som e are m ore act ive again st on e grou p versus th e oth er. An t ibiot ics su ch as polym yxin B, w h ich is effect ive on ly

Fig . 14.1 Bacterial corneal ulcer

with hypopyon. (Courtesy of Nibaran Gangopdhyay)

405

406 Color Atlas of Ophthalm ology

Table 14.1 Topical Antibacterial Agents

 

Trade

Antibacterial

 

 

 

 

Nam e

Agent

Chem ical Class

Form ulation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bleph-10

Sulfacetamide

Sulfonamide

10% solution

 

 

Sulamyd

sodium

 

10% ointment

 

 

 

 

 

 

Generic

Bacitracin

Peptide

500 Units/g ointment

 

 

Generic

Erythromycin

Macrolide

0.5% ointment

 

 

Genoptic

Gentamicin

Aminoglycoside

0.3% solution

 

 

Garamycin

 

 

0.3% ointment

 

 

Tobrex

Tobramycin

Aminoglycoside

0.3% solution

 

 

 

 

 

0.3% ointment

 

 

Ciloxan

oxacin

Second-generation

0.3% solution

 

 

 

 

uoroquinolone

0.3% ointment

 

 

ox

oxacin

Second-generation

0.3% solution

 

 

 

 

uoroquinolone

 

 

 

Quixin

oxacin

Third-generation

0.5% solution

 

 

 

 

uoroquinolone

 

 

 

Zymar

 

Fourth-generation

0.3% solution

 

 

 

 

uoroquinolone

 

 

 

Vigamox

oxacin

Fourth-generation

0.5% solution

 

 

 

 

uoroquinolone

 

 

 

 

 

 

 

 

 

 

 

 

 

 

again st gram -n egat ive bacteria, are com bin ed w ith oth er an t ibiot ics to in crease th e spect rum of coverage (Table 14.2). Som e of th ese an t ibiot ics are form ulated as aqueous drops or oin t m en t . Oth ers com bin e an t iin flam m ator y agen t s to reduce a h ost in flam m ator y respon se th at can be as dam aging to ocular t issues as bacterial proteases an d toxin s (Table 14.3).

Table 14.2 Com binations of Antibacterial and

am m ato ry Drugs w ith

Polym yxin B

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade

Antibacterial

 

 

 

 

Nam e

Agent(s)

Chem ical Class

Form ulation

 

 

 

 

 

 

 

 

 

 

 

 

Polysporin

Bacitracin

Peptide

500 Units/g ointment

 

Neosporin

Neomycin +

Aminoglycoside +

3.5 mg/g ointm ent

 

ointment

bacitracin

peptide

400 Units/g ointm ent

 

Neosporin

Neomycin +

Am inoglycoside +

10,000 Units;

 

solution

gramicidin

peptide

1.75 mg/mL solution

 

 

 

 

0.025 mg/mL solution

 

Terramycin

Oxytetracycline

Tetracycline

5 mg/g ointment

 

Polytrim

Trim ethoprim

Diaminopyrimidine

1 m g/mL solution

 

 

 

 

 

 

 

 

 

 

 

 

14 Ophthalmic Pharmacology 407

408 Color Atlas of Ophthalm ology

Table 14.4 Injectable Antibacterial Agents

 

Antibacterial

 

Trade

 

Route of

 

 

Agent

Chem ical Class

Nam e

Dosage

Injection

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gentamicin

Aminoglycoside

Garamycin

20 mg/0.5 mL

Subconjunctival

 

 

Am ikacin

Am inoglycoside

Amikin

250 µg/0.1 mL

Intravitreal

 

 

Vancomycin

Glycopeptide

Vancocin

2 mg/0.2 mL

Intravitreal

 

 

 

 

 

25 m g/0.5 m L

Subconjunctival

 

 

Ceftazidim e

Third-generation

Fortraz

2.2 mg/0.1 mL

Intravitreal

 

 

 

cephalosporin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Injectable Antibacterial Agents

Bacterial in fect ion s of th e posterior por t ion of th e eye (en dop h th alm it is)

are

t reated w ith an t ibiot ics injected subconju n ct ivally or in t ravit really. Curren t

an -

t ibiot ic t reat m en t regim en s are listed in Table 14.4. Dosage recom m en dat ion s for th ese an t ibiot ics sh ould n ot be exceeded to avoid in ducing ret in al toxicit y. Adm in - ist rat ion of th ese an t ibiot ics is con t rain dicated w h ere th ere is a kn ow n hypersen - sit ivit y to th ese agen ts.

Ocular Antivirals

More th an 45 years ago, Kaufm an first repor ted th e u se of idoxuridin e (Herp lex) for th e t reat m en t of h erpes sim plex viru s (HSV) epith elial kerat it is (Fig. 14.2). Sin ce th en , 50 an t ivirals h ave been licen sed in th e Un ited St ates; 10 n ew an t ivirals an d com bin at ion s h ave been in t rodu ced in th e last 10 years. Acyclovir (ACV) (Zovirax) h as been called th e “pen icillin of an t ivirals.” Th ere are th ree an t ivirals th at h ave purin e st r uct ures sim ilar to ACV: valacyclovir (Valt rex), fam ciclovir (Fam vir), an d gan ciclovir (Cytoven e, Vit raset). Idoxuridin e (Herp lex) an d t rifluorothym idin e (Viropt ic) h ave ver y sim ilar pyrim idin e st ru ct u res. Viropt ic is th e drug of ch oice for HSV pat ien ts. Table 14.5 is a sum m ar y of th e m ost im por tan t an t ivirals an d th eir th erapeu t ic use in viral in fect ion s of th e eye.

Fig . 14.2 Herpes simplex viral keratitis with large dendrite in late untreated stage.

14 Ophthalmic Pharmacology 409

410 Color Atlas of Ophthalm ology

Table 14.6 Antifungal Agents to Treat Fungal Keratitis and Endophthalm itis

 

Antifungal

Chem ical

Trade

 

Route of

 

Agent

Class

Nam e

Dosage

Adm inistration

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Natamycin

Polyene

Natacyn

5% suspension

Topical

 

Amphotericin

Polyene

Fungizone

0.1–0.5% solution

Topical

 

B

 

 

0.8–1.0 mg

Subconjunctival

 

 

 

 

5 µg

Intravitreal

 

Miconazole

Imidazole

Micatin

1% solution

Topical

 

 

 

 

5–10 mg

Subconjunctival

 

 

 

 

10 µg

Intravitreal

 

Voriconazole

Triazole

Vfend

1% solution (made

Topical

 

 

 

 

from IV solution;

 

 

 

 

 

 

dosing ranges from

 

 

 

 

 

 

hourly to t wice a

 

 

 

 

 

 

day as determined

 

 

 

 

 

 

by clinician.

 

 

 

 

 

 

200 mg t wice daily

Oral

 

 

 

 

3–6 mg/kg every

IV*

 

 

 

 

12 h

 

 

 

 

 

 

*Becau se of poten t ial

ect s an d toxicit y, the pract it ion er sh ould con sult the Physicians’ Desk

Reference for possible dosage adjust m en ts an d w arn ings.

 

 

Abbreviat ions: IV, in t ravenous.

 

 

 

 

Antifungal Agents

Th ere is on ly on e com m ercially available topical an t ifu ngal drug (Table 14.6): n a- t am ycin (Nat acyn ). Th e rem ain ing an t ifungal agen t s in Table 14.6 m u st be extem - poran eou sly com poun ded for topical, subconju n ct ival, or in t ravit real use. All of th ese agen ts are effect ive again st yeast an d filam en tou s fu ngi. Because of poor pen et rat ion , all of th ese an t ifungal agen t s adm in istered topically for corn eal in fec- t ion s are dosed at h ou rly or 2-h our in ter vals for th e first 2 or 3 days. Th e dosing sch edu le m ay be exten ded to a drop six to eigh t t im es a day, depen ding on h ow th e in fect ion is resolving. Drug pen et rat ion in to corn eal t issu e im proves if th e epith elium is absen t . Adverse react ion s to topical an t ifungal agen ts are lim ited to local hypersen sit ivit y react ion s (e.g., conjun ct ival ch em osis an d hyperem ia, foreign body sen sat ion ).

Antiparasite Agents

Exogen ou sly acqu ired parasite in fect ion s of th e eye are cau sed prim arily by am oeba of th e gen u s Acantham oeba. Th ere are n o ch em oth erapeu t ic agen t s app roved by th e Un ited States Food an d Drug Adm in ist rat ion specifically for th e t reat m en t of Acantham oeba kerat it is. How ever, an over-th e-cou n ter arom at ic diam idin e available in th e Eu ropean Un ion , propam idin e iseth ion ate (Brolen e), h as been sh ow n to be effect ive w h en com bin ed w ith th e an t ibacterial drug n eom ycin . Propam idin e iseth ion ate is available as a 0.1%solut ion or as an oin t m en t (0.15%).